Page 117 - Drug Class Review

Drug Effectiveness Review Project

Drugs Authors: Homma et al. 41 To evaluate efficacy and safety of DON at 5 mg/d in patients with mild to moderate AD over 24 weeks Setting: Multi-center (54) placebo donepezil N/A 5 mg/d 24 weeks 24 weeks 112 116 Outpatients diagnosed as having AD by the diagnostic criteria of DSM-IV; CDR of (1) mild or (2) moderate; MMSE score of 10-26 points; ADAS-J-Cog score of at least 15 points Patients with neurological signs such as parkinsonism; patients with definite symptoms of depression, and patients with old had trauma associated with disturbances of consciousness;

Alzheimer Year: 2000 Country: Japan NR Study design: RCT Sample size: 268 rehabilitation

Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs